In this video, Gavin Jones outlines how an outcomes audit and evaluation can help a healthcare provider or a commissioner such as the NHS to get an better understanding in terms of the level of scale and level of investment required to accommodate a new therapy within a treatment pathway, and can help bio pharma to differentiate their treatment against competitors. By jointly working with the NHS to develop an outcomes evaluation, biopharma can potentially build stronger relationships and support the NHS in managing change, demonstrating a stronger commitment - to the treatment, to the NHS, and to the patients that potentially will benefit from it.